Psych Congress NetworkSingle-Dose LSD Formulation Hits Primary Endpoint in Phase 3 MDD Trial

⚠️ Small Study / Early Comparative Evidence

The phase 3 Emerge trial randomized 149 adults with major depressive disorder to receive a single dose of DT120, an orally disintegrating LSD formulation, or placebo. Investigators reported greater improvement in depression scores with DT120 at weeks 1, 6, and 12.

Clinical Considerations

• DT120 produced greater MADRS improvement than placebo at week 6 (LS mean difference -8.1; p<0.0001).
• Antidepressant effects appeared within one week and persisted through 12 weeks after a single dose.
• Investigators reported no increase in suicidal ideation and no new safety signals.
• Findings currently derive from company-reported topline data without full peer-reviewed publication.

Practice Applications

• Interpret these findings as preliminary evidence pending full peer-reviewed analysis.
• Recognize ongoing interest in psychedelic-based therapies for major depressive disorder.
• Monitor forthcoming efficacy and safety data from the ongoing Ascend phase 3 study.
• Avoid assuming comparative effectiveness against established depression treatments.